share_log

HC Wainwright & Co. Initiates Coverage On Reneo Pharmaceuticals With Buy Rating, Announces Price Target of $30

Benzinga ·  Aug 28, 2023 06:15

HC Wainwright & Co. analyst Gobind Singh initiates coverage on Reneo Pharmaceuticals (NASDAQ:RPHM) with a Buy rating and announces Price Target of $30.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment